Simvastatin can inhibit the proliferation of HCC cells by inhibiting PKM2-mediated glycolysis, inhibiting the HIF-1α/PPAR-γ/PKM2 axis, and increasing the sensitivity of HCC cells to sorafenib [159]. This evidence concerns the gene PKM and hepatocellular carcinoma.